‘The chief executive officer of Schering-Plough Corp. on Monday said he is interested in pursuing drugs that boost “good” HDL cholesterol and is hopeful the company’s experimental hepatitis C drug will eclipse current treatments in safety and effectiveness.

“Now that Schering-Plough has become strong in cardiovascular medicine, we are looking at the HDL area and think it is a very good area to be in,” Fred Hassan said in an interview.’

Read more at Schering-Plough CEO mulls HDL-raising drugs

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Tuesday, January 31st, 2006 at 2:21 am and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.